

Aurorium Expands as Innovative Partner for Drug Delivery in Pharmaceuticals

The rapidly evolving pharmaceutical market is demanding novel solutions that enhance drug efficacy, improve patient compliance, and streamline manufacturing processes. As a trusted partner to pharmaceutical manufacturers, Aurorium has risen to the occasion, leveraging its innovative research and development capabilities to offer tailored solutions that address specific drug delivery challenges faced by the industry.

To solidify their commitment to drug delivery platforms, Aurorium has made strategic investments in expanding capabilities serving the **pharmaceutical** sector, specifically additional capacity for the manufacturing of caustic pellets.

Sodium Hydroxide is used by the large molecule biologics industry in both the upstream (cell culture) and downstream (separation & purification and fill & finish) processes

Potassium Hydroxide is used in soft gel capsules to enhance the solubility of acidic active pharmaceutical ingredients (APIs)

Jenny Titova, Strategic Marketing Manager - Pharmaceuticals, said, "This investment underscores Aurorium's strategic focus on life sciences. It reinforces our leading position in North America and strengthens our supply capabilities globally as we continue to expand with our customer base."

Aurorium's comprehensive portfolio of specialty solutions are designed to optimize drug delivery systems, enabling pharmaceutical companies to enhance the therapeutic efficacy of their products while ensuring patient safety and convenience. Aurorium provides a range of solutions for drug delivery systems that encompass:

Formulation Development:

collaborating closely with pharmaceutical manufacturers as they develop drug formulations, ensuring optimal bioavailability, controlled release, and stability

Controlled Release Systems:

controlled release systems that enable sustained drug release over extended periods, improving patient compliance and reducing dosing frequency

Excipient Solutions:

a broad selection of excipients, including functional plasticizers, buffers, coating agents, and vaccine adjuvants, which play a crucial role in the formulation and delivery of pharmaceutical products

Dr. Steve Tattum, Vice President of Aurorium Specialty Solutions, added, "These capital investments follow multiple strategic acquisitions, expanding our **Healthcare** portfolio and emphasizing our commitment to the global pharmaceutical market. The continued growth will strengthen our global position in the biopharmaceutical markets as a reliable and dedicated partner."

"The continued growth will strengthen our global position in the biopharmaceutical markets as a reliable and dedicated partner."

Dr. Steve Tattum, Vice President

By partnering with Aurorium, pharmaceutical manufacturers gain access to a wealth of technical expertise, cutting-edge research, and an unwavering commitment to quality. With a relentless pursuit of innovation and a dedication to customer satisfaction through supporting the consumer experience, Aurorium is positioned to be an innovative partner for drug delivery systems.

About Aurorium

Aurorium is the materials innovation partner that helps global manufacturers harness the power of possibility to make the world a better place. Their specialty ingredients and performance-enhancing materials enhance quality of life, support health and wellness, and enable customers to deliver value-added solutions. Key industries served include personal & home care, coatings & adhesives, energy & electronics, healthcare, food & beverages, agriculture, transportation, and paper & packaging. A Responsible Care® company, Aurorium follows the highest regulatory standards across all of its manufacturing facilities. Aurorium is committed to operating at the highest levels of manufacturing consistency, quality control, and safety.

